Zealand Pharma Establishes Research Hub in Cambridge to Strengthen Drug Discovery Capabilities
Wednesday, March 25, 2026
Zealand Pharma has announced the establishment of a new research hub in Cambridge, Massachusetts, as part of its efforts to expand global drug discovery and development capabilities.
The facility will serve as the company’s primary base in the United States and is expected to become operational in September 2026.
The new site is intended to strengthen Zealand Pharma’s research footprint alongside its existing operations in Denmark. It will support the company’s long-term ambition to advance its position in obesity and metabolic health.
Located in one of the world’s leading life sciences clusters, the Cambridge hub will enable the company to access skilled talent, advanced technologies, and potential research collaborations. The facility will focus on enhancing research through artificial intelligence-driven drug discovery, automation, and advanced molecular design, with the aim of accelerating the development of new medicines.
The site, situated at CambridgePark Drive, will also support collaboration with local partners to develop artificial intelligence, machine learning, and automation models. These technologies are expected to improve the efficiency and quality of drug design and broaden the company’s research capabilities.
The expansion will allow Zealand Pharma to move beyond its core peptide expertise by incorporating additional modalities, including antibody-peptide conjugates and small interfering RNA approaches. This aligns with the company’s broader research and development strategy.
In addition to laboratory space, the Cambridge facility will include offices and collaborative areas to support growing teams in the United States. The company has also begun recruitment efforts for the new site.
Zealand Pharma, founded in Denmark, has built its research capabilities over nearly three decades, particularly in peptide-based therapeutics, and continues to expand its global presence through strategic investments in innovation hubs.
Source: zealandpharma.com
